Skip to main
NGNE

Neurogene Inc (NGNE) Stock Forecast & Price Target

Neurogene Inc (NGNE) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Neurogene is a promising biotechnology company with a differentiated product portfolio targeting rare neurological diseases through its proprietary transgene regulation technology, EXACT. Their clinical data for NGN-401 in the treatment of Rett syndrome and NGN-101 for CLN5 Batten disease have shown promising results and emboldened our confidence in their ability to successfully develop these treatments. While there are inherent risks in the biotech industry, we believe Neurogene's execution and continued focus on innovative treatments will result in strong product revenue growth in the future.

Bears say

Neurogene is a clinical-stage biotechnology company with a focus on developing genetic medicines for rare neurological diseases through its proprietary EXACT platform. Its latest drug candidates NGN-401 and NGN-101 show potential in treating Rett syndrome and CLN5 Batten disease, respectively. With a recent financing of $135 million and ongoing PPQ campaign, the company's cash runway is extended into 2029. The longer-term data of NGN-401 positions it as a potential competitor to TSHA, and the analyst has raised the price target to $81. However, concerns remain about the delay in the Ph 1/2 data presentation and the company's future profitability.

Neurogene Inc (NGNE) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurogene Inc (NGNE) Forecast

Analysts have given Neurogene Inc (NGNE) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Neurogene Inc (NGNE) has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $90.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $90.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurogene Inc (NGNE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.